MTOR and COVID-19: The overall proportion of immunocompromised individuals did not differ between the two groups (39 [23.5%] vs 69 [27.1%]; P = 0.43), but COVID-19 patients significantly more often received chemotherapy (20 [12.0%] vs 11 [4.3%]; P = 0.004), CD20 antibodies (9 [5.4%] vs 2 [0.8%]; P = 0.008) or suffered from acute leukemia (13 [7.8%] vs 6 [2.4%]; P = 0.01), while influenza patients were more often treated with systemic corticosteroids (13 [7.8%] vs 40 [15.7%]; P = 0.04) or calcineurin and mTor-inhibitors (6 [3.6%] vs 29 [11.4%]; P = 0.006).